Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Helping The Blind To See: Medtech Start-Ups Focus On Vision Restoration

Executive Summary

In recent years, medtech start-ups have made great strides in developing technologies to treat eye disease such as cataracts, diminishing vision, and even dry eye. But the greatest leaps – or the most life changing – may have been executed by companies such as Second Sight Medical Products Inc. and Wicab Inc. that are finding ways to actually help blind people see.

You may also be interested in...

US Neurostimulation Devices Market Forecast to Grow By $1B+ With New Indications, New Technologies

The US neurostimulation technology market will grow nearly 46% over the next five years, according to a new report from Medtech Insight.

Targeting The Tongue: Helius Medical’s Unique Approach To Neuromodulation Tested In Trials

Neuromodulation start-up Helius Medical Technologies is employing a simpler, more primal connection to send potentially therapeutic signals to the brain – the tongue. The company is entering pivotal clinical trials to test the technology in select patients with traumatic balance disorder and traumatic brain injury, and evaluating the device for use in patients with multiple sclerosis.

Second Sight Shows The Way

Second Sight secured FDA approval for the Argus II Retinal Prosthesis System in 2013 and followed it with an IPO, giving the company the capital necessary to expand the commercial launch of its system to restore the vision of patients blinded by retinitis pigmentosa while also developing a new system that might restore the vision of anyone who has lost their sight to disease. An interview with CEO Robert Greenberg, MD.


Related Companies

Related Deals

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts